Genovis AB (publ.) (5GV.F)

2.1650 -0.1000 (-4.42%) As of 09:15AM CEST. Market open.

Genovis AB (publ.)

Box 4
Kävlinge 244 21
Sweden
46 46 10 12 30
https://www.genovis.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 37

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Fredrik Olsson	President & CEO	2.69M	N/A	1971
Mr. Magnus Langberg	Group Chief Financial Officer	N/A	N/A	1971
Ms. Susanne Ahlberg	General Counsel	N/A	N/A	1957
Ms. Rikke Rytter	Vice President of Sales & Marketing	N/A	N/A	1967
Ms. Maria Edholm	Controller	N/A	N/A	N/A
Mr. John M. Lindsay B.A., BA	President of Genovis Inc.	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics for customers in the pharmaceutical and research industries. The company provides FabALACTICA, a cysteine protease; FabRICATOR, a cysteine protease; and FabRICATOR Z, for the digestion of mouse IgG2a and IgG3, and generating a homogenous pool of F(ab')2 and Fc fragments. It offers FabULOUS (SpeB), a cysteine protease; GingisKHAN, a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. In addition, the company offers GingisREX, a protease that digests proteins C-terminally of arginine residues; GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology; TransGLYCIT, a platform technology; OmniGLYZOR, a mixture of immobilized enzymes; PNGase F, a glycoamidase; and OpeRATOR, an O-glycan-specific protease. Further, it provides OglyZOR, an endoglycosidase; SialEXO, a sialidase product; FucosEXO, a mix of a-Fucosidases; GalactEXO, a ß-Galactosidase mix; GalNAcEXO, an a-N-Acetylgalactosaminidase; GlycOCATCH, an affinity resin; GlycINATOR (EndoS2), an IgG-specific endoglycosidase; IgGZERO (EndoS), an IgG-specific endoglycosidase; Anti-FabRICATOR (Anti-IdeS), a goat polyclonal antibody; and Anti-FabRICATOR Z (Anti-IdeZ), a goat polyclonal antibody. Additionally, the company offers antibodies, assay kits, reagents, and cell culture products; bioprocess and gene therapy services; and services, such as SmartEnzymes fragmentation and conjugation, antibody LC-MS analysis, and customized antibody services, as well as operates an online store for its products. It serves pharmaceutical and biotech, contract research, and contract manufacturing companies in Europe, North America, and Asia. The company was founded in 1999 and is headquartered in Kävlinge, Sweden.

Corporate governance

Genovis AB (publ.)’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.